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1INTRODUCTION
As of the end of 2003, an estimated 42 million people worldwide - 38.6
million adults and 3.2 million children younger than 15 years - were living with
HIV/AIDS. Approximately 70 percent of these people (29.4 million) live in
Sub-Saharan Africa; another 17 percent (7.2 million) live in Asia
(1).Worldwide, approximately twelve of every 1000 adults aged 15 to 49 are
HIV-infected. In Sub-Saharan Africa, about 9 percent of all adults in this age
group are HIV-infected. In 4 African countries, the prevalence of HIV infection
among adults aged 15 to 49 exceeds 30 percent (1) .Approximately 50 percent
of adults living with HIV/AIDS worldwide are women. An estimated 5 million
new HIV infections occurred worldwide during 2003; that is, about 14,000
infections each day. More than 95 percent of these new infections occurred in
developing countries. In 2003, approximately 2,000 children under the age of
15 years, and 6,000 young people aged 15 to 24 years became infected with
HIV every day. In 2003 alone, HIV/AIDS-associated illnesses caused the
deaths of approximately 3.1 million people worldwide, including an estimated
610,000 children younger than 15 years.: The first HIV case in India was
reported in 1986 in Tamil Nadu.  The estimated number of adults living with
HIV/AIDS by end of 2003 is 50 lakhs of which children form 1.2 lakhs and
women 1.9 lakhs.  Indian statistics reveal the high HIV prevalence states in
India to be Tamil Nadu, Karnataka, Andhra Pradesh, Maharashtra, Nagaland
and Manipur where HIV infection has crossed 1% or more in antenatal women.
The national HIV prevalence in adult population is 0.9%.
2Pediatric AIDS threatens much of the progress made in child survival in
developing countries over the past 10 to 15 years.  It is estimated that more
than 8 lakhs of new pediatric infections are acquired, world wide, every year
mostly through maternal foetal transmission.
THE VIRUS: ( 22)
HIV types 1 and 2 are members of the retroviridae family and belong to
the lenti virus genus. The HIV genome is a single stranded RNA 9.8 kb in size,
with identical regions at both ends of the genome that contain important
regulatory genes. The remainder of genome includes 3 major coding regions.
The GAG region encodes the viral core proteins. The POL region
encodes the viral enzymes. The ENV region encodes the viral envelope
proteins gp 120 and gp 41. Other proteins are involved in Transcription
(TAT),viral mRNA expression(REV), viral enhanced infectivity (NEF).
The major external viral protein of HIV is gp120, a heavily glycosylated
protein associated with the transmembrane glycoprotein gp41. the gp41 is very
immunogenic and is used to detect HIV antibodies in diagnostic assays.
Secondary receptors for attachment have also been identified, including
the fusion inducing molecule CXCR-4 which is a co-receptor for HIV
attachment to lymphocytes, and CCR-5,a β chemokine receptor which
facilitates HIV entrance into macrophages.
3TRANSMISSION
Transmission of HIV occurs via sexual contact, parenteral exposure to
blood, or vertical transmission from mother to child. The primary route of
infection in pediatric population is vertical transmission, accounting for
virtually all new cases. Reported vertical transmission rates are between 20-
40%. Perinatal treatment of HIV infected mothers with anti-retro viral drugs
can dramatically reduce rates to less than 8%.
Vertical transmission of HIV (12, 13, 14) can occur before (intrauterine),
during (intrapartum), or after delivery (through breast feeding) .Intrauterine
transmission(21) can occur as early as 10 weeks of gestation. It is generally
accepted that 30-40% of infected newborns are infected in-utero, because this
percentage of infants have lab evidence of infection (positive viral culture)
within first week of life.
The highest percentage of HIV infected children acquire the virus
intrapartum, evidenced by finding that 60-70 % of infected infants do not
demonstrate virus before 1 week of life. The mechanism of transmission
appears to be exposure to infected blood and cervico vaginal secretions in the
birth canal, where HIV is found in high titer during late gestation and delivery.
Several risk factors influence the rate of vertical transmission : preterm
delivery, low birth weight, low maternal antenatal CD4+ counts and IV drug
use during pregnancy. The single most important variable appears to be more
than 4 hr duration of ruptured membranes , which doubles the transmission
4rates. Caesarean section may confer a protective effect compared to vaginal
delivery.
The risk of transmission of HIV infection to infants by breast feeding (15)
appears to be around 14%.WHO recommends that in developing countries the
benefits of breast feeding outweighs the risk of HIV transmission, and HIV
infected women should breast feed their children.
Transfusions of blood and blood products accounted for about 3-6% of
pediatric HIV infections in the past. However this is on the decline now .
Sexual transmission in the pediatric population is infrequent but a small
number of cases relating to sexual abuse have been reported.
PATHOGENESIS: (23,24)
In adults and adolescents, after HIV has entered the circulation, intense
viremia ensues causing flu like illness in 50-70% of cases. This results in
widespread seeding of virus to various organs, including the brain and
lymphoid tissues. HIV selectively binds to cells expressing the CD4+
molecules on their surface and cells of monocyte macrophage lineage. HIV
may also infect other cells such as microglia,astrocytes,oligodendroglia,and
placental tissue containing  villous Hofbauer cells.With establishment of a
cellular and humoral immune response within 2-4 months,the level of
culturable virus from blood declines and patients enter a phase characterized by
a lack of symptoms and the return of CD4+ cells to only moderately decresed
levels.
5Early HIV infection and replication in children have no apparent clinical
consequences.Whether  tested by virus isolation or by PCR ,less than 50% of
HIV –infected infants demonstrate evidence of virus at birth. The virus load
increases by 1-4 months and almost all HIV infected infants have demonstrable
HIV in peripheral blood by 4 months of age.
Three distinct patterns of disease has been described in children. From
15-25% of HIV infected newborns have a rapid disease course,with onset of
symptoms  and AIDS during the first few months of life and if untreated , a
median survival of  6-9 months(28). The majority of perinatally infected
newborns 60-80% present with a much slower progression of disease,with
median survival of 6 years.Many  patients in this group have a negative viral
culture or PCR test in the first week of life and , are therefore, considered to be
infected intrapartum. The viral load increases slowly by 2-3 months of age and
then slowly declines over a period of 24 months.
The third pattern of disease involves the long term survivors, which
occurs in a small percentage <5% of perinatally infected children who have
minimal or no progression of disease with relatively normal levels of CD4+
counts and very low viral loads for more than 8 years.
CLINICAL MANIFESTATIONS: (26)
The clinical manifestations of HIV disease in children differ in
important ways from those seen in adults.
61. Overall progression of disease is more rapid.
2. Recurrent invasive bacterial infections more common
3. Disseminated CMV, Candida, Herpes simplex and     Varicella
zoster infections more common.
4. 20-40% children have encephalopathy
5. Malignancies, neuropathy and myopathy are uncommon.
6. Lymphocytic Interstitial Pneumonitis (LIP) occurs almost
exclusively in children.
Bacterial Infections(31)
The incidence of invasive bacterial disease, including meningitis,
bacteremia, or pneumonia is higher than among adults. Other bacterial
infections, including sinusitis, otitis media, deep tissue abscesses,
osteomyelitis,ocular infections(50) and septic arthritis are also more prominent.
Cardiac Involvement
Cardiac disease, including cardiomyopathy, congestive heart failure, and
conduction defects is increasingly recognized. Sub clinical myocardial
dysfunction is extremely common when routine echocardiography is done.
However, in a prospectively studied cohort, the cumulative incidence of overt
congestive heart failure was 12% at 2 years. The etiology is poorly understood,
but HIV RNA has been isolated from myocardial cells. Left ventricular
7dysfunction is correlated with the presence of encephalopathy and is an
independent predictor of mortality.
Gastrointestinal Involvement (29)
Gastrointestinal complications of HIV are common in children. Thrush
persisting more than 2 months is considered a category B symptom, but other
oral manifestations are common. These include candidiasis, linear gingival
erythema, herpes stomatitis, necrotizing gingivitis, salivary gland enlargement
and aphthous ulcers. Aphthous ulcers are more common in children who are
HIV-infected and can involve the esophagus, stomach, rectum, or vulva. Both
acute and persistent diarrhea are major causes of morbidity in developed
countries. In developing countries, diarrhea is a major cause of death, and,
HIV-infected children had an 11-fold increase in risk of death from diarrhea
compared to uninfected infants of HIV-infected mothers. The spectrum of
diarrheal pathogens is incompletely studied. In general, the pathogens are those
common in uninfected children in the region, including Salmonella, Shigella,
Campylobacter, rotavirus, and enterotoxigenic, enteroaggregative and locally
adherent phenotypes of diarrhea-causing Escherichia coli. However, disease is
more frequent, more severe, and more likely to be persistent. Cryptosporidiosis
and microsporidiosis are late complications.
Pulmonary Involvement
The most important pulmonary complications of HIV in children
include bacterial pneumonia, Pneumocystis carinii pneumonia(25,39), and
8lymphoid interstitial pneumonitis (LIP). The classic reticulonodular findings of
LIP may be noted on chest x-ray when the child is asymptomatic and has
normal oxygen saturation. As the disease worsens, hypoxia and clubbing may
develop. Severe LIP responds to steroids, but the presence of LIP is actually
associated with improved survival compared to other manifestations of AIDS.
Renal Involvement(30)
Renal involvement occurs in 2 to 10% of HIV-infected children in the
United States. HIV nephropathy can range from mild proteinuria to nephrosis,
renal tubular acidosis, hematuria and acute renal failure. In adults in the United
States, there is a markedly increased risk of nephropathy among black persons
with HIV infection; this appears to be true in children as well but the data are
sparse.
Central Nervous System Involvement: (27)
Central nervous system involvement is a common and serious
complication of HIV infection in children. Encephalopathy that meets the CDC
definition represents the more severe end of the clinical spectrum. Among 1811
children followed in the Pediatric Spectrum of Disease Project, 23% were
diagnosed with encephalopathy. In the WITS study of 124 children with a
median of 24 weeks of follow-up, 21% of children developed encephalopathy.
Milder neurologic dysfunction and developmental difficulties are even more
common. A comparison of encephalopathy in adults and children in 2
prospective cohorts found striking differences between children and adults in
9early onset encephalopathy, but fewer differences later in disease. The
incidence of encephalopathy was 9.9% in children compared to 0.3% in adults
in the first year, 4.2% compared to 0% in second year, but about 1% per year
thereafter in children as well as adults. Early onset encephalopathy was more
severe, was associated with less immunosuppression, and resulted in more
dramatic brain atrophy and prominent motor findings in children than in adults.
It is hypothesized that the encephalopathy shared by older children and adults
occurs by a different process than the devastating early onset encephalopathy
of infants. A formal developmental or neurologic assessment should be
performed periodically in all infected children.
Malignancies(48)
AIDS-associated malignancies in children differ from those in adults.
Non-Hodgkin's lymphoma is the most common malignancy, and GI tract
involvement is common. The second most commonly reported malignancy is
leiomyosarcoma, a disease that is extraordinarily rare in adults. Kaposi's
sarcoma, common among HIV-infected gay men, is very rare in children in
developed countries.
Growth & Nutrition
Growth failure is a prominent feature of untreated HIV infection.
Stunting, or low height for age, is more prominent than wasting. Growth
velocity clearly increases with effective antiretroviral therapy but often does
not return to normal. Nutritional assessment is important in all infected children
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to maximize growth. It is particularly important in children with advanced
disease who may suffer poor appetite, nausea, gastroparesis, increased
metabolic demands, diarrhea, or malabsorption. Comprehensive nutritional
assessment is useful for all HIV-infected children. Growth hormone has been
used to treat persistent growth failure in some children.
Tuberculosis in HIV infection:(18)
Tuberculosis is not only the commonest opportunistic infection, but also
the earliest manifestation of HIV.Tuberculosis occurs in HIV infected patients
without pre-existing AIDS. This is presumably because of M.tuberculosis
being more virulent than other HIV associated pathogens such as P.carinii or
M.avium complex. HIV infected children usually develop progressive primary
tuberculosis,following recent infection.Clinical and radiological manifestations
do not vary significantly from those who are seronegative. Extra pulmonary
tuberculosis is common, with lymphadenopathy, pleural effusion and miliary
TB being the major types. Majority of TB cases in children are diagnosed
clinically without microbiologic confirmation. Tuberculin skin test is more
often negative , in children with advanced HIV disease, complicating the issue
of diagnosing tuberculosis.
CLINICAL CLASSIFICATION
In the 1994 revised clinical classification of Pediatric HIV infection ,
children are classified as asymptomatic (Category N), mildly symptomatic with
HIV-related symptoms (Category A), moderately symptomatic (Category B)
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with significant HIV-related symptoms but no Category C symptoms, and
Category C which includes AIDS-defining illnesses as outlined in the 1987
case definition.
In addition to providing a useful standard for evaluating children, the
revised classification system has been shown to be useful for establishing
prognosis and modeling the course of disease although further modifications
have been proposed.
Most children will present for medical care with category A symptoms,
but due to the non-specific nature of these symptoms, HIV may not be
suspected or diagnosed. Many women with HIV infection do not have easily
identified risk factors, so a high index of suspicion is needed. Hepatomegaly
and lymphadenopathy are the most common category A findings. Parotitis is
less common but more striking. The histologic findings demonstrate a dense
infiltrate of CD8 cells within the gland. Cystic degeneration may be seen, and
lymphoma within the parotid may develop in rare cases. The triad of
lymphadenopathy, splenomegaly, and failure to thrive is strongly suggestive of
HIV infection, and testing should be performed.
Category B symptoms indicate more severe disease. Based on Markov
modeling, children spend the longest time in Category B, a mean of 65 months
compared to 10 months in Category A and 35 months in Category C
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Table 1: 1994 Revised human immunodeficiency virus pediatric
classification system: Immune categories based on age-
specific CD4 + T lymphocyte and percentage.(20)
<12 months 1-5 years 6-12 years
Category No. /
microliter
(%) No. /
microliter
(%) No. /
microliter
(%)
Category 1
No suppression
>1,500 (>25%) >1,000 (>25%) >500 (>25 %)
Category 2
Moderate
suppression
750-1,499 (15%-
24%)
500-999 (15%-
24%)
200-499 (15%-
24%)
Category 3
Severe suppression
<750 (<15%) <500 (<15%) <200 (<15%)
Table 2: Revised Human Immunodeficiency Virus pediatric
classification system: Clinical categories(20)
Category N: Not Symptomatic
Children who have no signs or symptoms considered to be the result of
HIV infection or who have only one of the conditions listed in category A.
Category A: Mildly Symptomatic
Children with two or more of the following conditions but none of the
conditions listed in categories B and C:
• Lymphadenopathy (>0.5 cm at more than two sites; bilateral =
one site)
• Hepatomegaly
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• Splenomegaly
• Dermatitis
• Parotitis
• Recurrent or persistent upper respiratory infection, sinusitis, or
otitis media
Category B: Moderately Symptomatic
Children who have symptomatic conditions other than those listed for
category A or category C that are attributed to HIV infection. Examples of
conditions in clinical category B include but are not limited to the following:
• Anemia (<8gm/dL), neutropenia (<1,000/mm3), or
thrombocytopenia (<100,000/cu mm) persisting >30 days
• Bacterial meningitis, pneumonia, or sepsis (single episode)
• Candidiasis, oropharyngeal (i.e., thrush) persisting for >2 months in
children aged >6 months
• Cardiomyopathy
• Cytomegalovirus infection with onset before age 1 month
• Diarrhea, recurrent or chronic
• Hepatitis
• Herpes simplex virus (HSV) stomatitis, recurrent (i.e., more than two
episodes within 1 year)
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• HSV bronchitis, pneumonitis, or esophagitis with onset before age 1
month
• Herpes zoster (i.e., shingles) involving at least two distinct episodes
or more than one dermatome
• Leiomyosarcoma
• Lymphoid interstitial pneumonia (LIP) or pulmonary lymphoid
hyperplasia complex
• Nephropathy
• Nocardiosis
• Fever lasting >1 month
• Toxoplasmosis with onset before age 1 month
• Varicella, disseminated (i.e., complicated chickenpox)
Category C: Severely Symptomatic
Children who have any condition listed in the 1987 surveillance case
definition for acquired immunodeficiency syndrome, with the exception of LIP
(which is a category B condition).
Serious bacterial infections, multiple or recurrent
Candidiasis,esophageal or pulmonary
Coccidioidomycosis,disseminated
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Cryptococcosis,Extra-pulmonary
Cryptosporidiasis or isosporiasis with diarrhea persisting for more than
1 month
CMV disease with onset of disease after 1 month of age.
Encephalopathy ( atleast 1 of the following present for atleast 2 months
in the absence of concurrent illness other than HIV)
Failure to attain or loss of developmental milestones or loss of
intellectual ability
a. Impaired brain growth or acquired microcephaly as demonstrated
by CT or MRI
b. Acquired symmetric motor deficit manifested by 2 or more of
following: paresis,pathologic reflexes,ataxia,gait disturbances
c. HSV infection
d. Histoplasmosis,disseminated
e. Kaposi's sarcoma
f. Primary brain lymphoma
g. Burkitt’s or immunoblastic lymphoma
h. Mycobacterium tuberculosis,Disseminated or Extra pulmonary
i. Mycobacterium avium complex, disseminated
k. Disseminated  other or unspecified mycobacterium
16
l. Pneumocystis carinii pneumonia
m. Progressive multifocal leukoencephalopathy
n. Salmonella septicemia recurrent( non typhoid)
Toxoplasmosis Brain after 1 month age.
Wasting syndrome is defined as wasting in the absence of a concurrent
illness other than HIV infection that could explain:
1. Persistent weight loss >10% of baseline
OR
downward crossing of at least two of the following percentile lines on
the weight-for-age chart (95th, 75th, 50th, 25th, 5th) in a child >=1 year
of age OR
1. <5th percentile on weight-for-height chart on two consecutive
measurements >30 days apart
PLUS EITHER
chronic diarrhea (i.e., at least two loose stools per day for >30 days)
OR
• documented fever (for >30 days, intermittent or constant).
17
WHO has devised a staging system for HIV infection and disease in
children based on the fifth international WHO Workshop on clinical
management of HIV AIDS on 14th October 2003.
Category 1.
Asymptomatic
Generalized lymphadenopathy
Category 2.
Unexplained chronic diarrhea (> 1month)
Severe persistent or recurrent candidiasis
Weight loss or failure to thrive
Persistent fever(> 1month)
Recurrent severe bacterial infections
Category 3
AIDS defining opportunistic infections
Severe failure to thrive
Progressive encephalopathy
Malignancy
Recurrent septicemia or meningitis
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Clinical case definition for AIDS in children:
1. Two positive test for HIV infection (by ELISA,Rapid tests)in children
older than 18 months or confirmed maternal infection for children
younger than 18 months AND
2. Presence of atleast 2 major and 2 minor signs in the absence of a known
cause of immunosuppression
Major signs:
a. loss of weight or failure to thrive , not due to any other cause
b. chronic diarrhea for over 1 month
c. prolonged fever for over 1 month
Minor signs:
a. repeated common infections
b. generalized lymphadenopathy
c. oropharyngeal candidiasis
d. persistent cough for over a month
e. disseminated maculopapular dermatosis
PREVENTING MOTHER TO CHILD TRANSMISSION(5,6,7)
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A growing number of studies demonstrate the efficacy of various
perinatal antiretroviral regimens for preventing transmission of HIV from
mothers to babies. Taken together, these studies show that the rate of
transmission to the infant, which in untreated HIV-infected pregnant women
exceeds 20%, can be dramatically reduced by antiretroviral therapy given in
the perinatal period. Regimens found to be effective include treatment of the
mother in the third trimester of pregnancy and during labor, with subsequent
treatment of the infant for at least the first few days of life. Regimens begun at
the time of labor are effective (although somewhat less so) only if followed by
treatment of the infant, probably for several weeks. When prenatal care is
lacking, treatment of the infant alone, especially if done within the first 48
hours of life, also provides a reduction in transmission risk. The benefit of
perinatal treatment is diminished in breastfed infants compared with those who
are not breastfed; perinatal treatment in the setting of breastfeeding may serve
largely to shift part of the risk of infection from the peripartum period to
several months later. The risk of maternal-fetal transmission decreases with
decreasing viral load, and is very low in women receiving effective
antiretroviral therapy as a matter of routine care.The risk of transmission may
reach less than 1% in women with plasma HIV viral load <400 HIV RNA
copies/mL on treatment, which is considerably lower than the transmission
risks associated with older perinatal regimens . It should therefore be kept in
mind that these regimens are only interim measures. The true benefit of
treatment will be realized not simply when the rate of infant infection is
reduced, but when the health of the mother is preserved as well.
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DIAGNOSIS:  (32)
Kinetics of antibody response in an HIV infected person.
One should have knowledge about antibody response in HIV infected
person for optimum use of different tests during different stages of disease.
1. Viral entry in to body leads to transient period of high plasma viremia &
antigenemia. The levels come down with 1-2 months with concomitant
immune response.
2. Antibodies are produced against Structural proteins, regulatory
proteins,accesory protein. structural protein are strongly immunogenic
and almost all tests are based on antibody detection against them gag
protein are the  first to appear and first to decline. However antibody to
env protein persist throughout.
BASICALLY 3 TYPE OF TESTS
1) Anti HIV antibody tests
2) Virological tests
3) Surrogate markers
SPECIMEN  USED
Antibody detection Blood, serum, plasma
Antigen detection Serum,plasma,csf cell culture supernatant
Viral isolation & detection of
viral nucliec acid
Plasma, serum, csf , vaginal & cervical
secretions
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ANTI .HIV ANTIBODY TEST
1) Screening test - ELISA Rapid test
2) Supplementaltest - Western blot ,line immunoassay ,radio
immunoblot assay
ELISA
Most commonly performed test to detect HIV antibody
ELISA tests are scored as positive (reactive), indeterminate( partially
reactive)& negative (nonreactive). It has got a high sensitivity  of
approximately 99.5% , but it is not that specific.
False  positive tests occur in  no of  situation & these includes.
- Acute viral infection
- Recent influencza vaccination
- hepatic disease
- Auto antibodies
Elisa becomes positive  1-2 months after primary infection . Elisa  can
take up 3 hours to yield  result, but it. has the major advantage  of being
economical. (Single elisa cost you only RS 200)
RAPID TEST
They give results within minutes (3–30 minute)
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Most have senstivities & specifities 98% & 99% respectively
Advantages
 quicker  to perform and results are delivered on the same day
 Do not require batching
 Do not require specialised     equipment or trained personnel
The only disadvantage with rapid test is that it is expensive and
according to WHO guidelines ,An individual reactive  to three different system
of ELISA /rapid tests can be   to be said have HIV infection.
WESTERN BLOT
Western blot is the supplementary  test to confirm the result of a reactive
sample in developed countries, whereas ELISA / rapid tests  are also used to
confirm the  results of reactive samples in developing countries  . This is
because  Western blot & other supplemental test are more expensive & rather
difficult to interpret , can also have a minimum level  of false positive reactions
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Western blot detects different antibodies within the test serum, capable
of reacting with different Viral proteins. It is done by electrophoresis of plasma
on pre impregnated strip containing various HIV antigens. Western blot in is
reported as positive if at least 2 out of 3 bands are positive (P24, GP41,
GP120/160).
OTHERS SUPPLEMENTAL TESTS
1) Line immunoassay
2) Radio immunoblot assay(RIBA)
Patient who give indeterminate results need to be retested 8-12 weeks
later. Consistent indeterminate results need to be confirmed by  virological test.
VIROLOGICAL TEST
Virological test will be needed in  the following situations.
For the diagnosis of
1) HIV infection in the newborn
2) HIV infection during the window period
3) HIV infection in persons giving indeterminate WB/LIA/RIBA 
result
4) Monitor viral load during therapy.
5) Research activities.
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HIV P24 antigen
HIV P24 antigen is detected  and quantified using EIA  technique. It has
got sensitivity and specificity of about 77% and 95% respectively. It is
undetectable in asymptomatic patients and in infants as  it is present as immune
complex with anti P24 antibody.  The presence  and detection of P24 antigen
indicates high  level of viremia   and increased risk of clinical progression.
Immune complex dissociated P24 antigen has improved  sensitivity even
then the sensitivity level is  sub optimal for early diagnosis of  HIV in infants.
NUCLIEC ACID DETECTION
1) HIV DNA PCR ( Qualitative assay)
This detects the proviral DNA that has integrated with host cell
(Peripheral blood mononuclear cells). It has got high sensitivity  (96-95%) and
specificity (97-98%).
HIV DNA PCR is
- Used for  early diagnosis of  HIV infection in neonate
- to resolve indeterminate serological  tests,
HIV RNA ASSAYS
1) They are primarily used monitor disease progression and response to
antiretroviral therapy.
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2) HIV RNA analysis is used when there is high degree of viremia and
serological test are negative. It has got  100% sensitivity and with few
false positives, specificity’s may range from 97-98%. Because of the
false positive reactions  the use of these assay for the diagnosis of HIV
Infection is controversial.
VARIOUS ASSAYS
1) RT – PCR
2) NASBA – nucleic Acid sequence based amplifications
3)  ‘b’ DNA technique
The lower level of quantification of HIV RNA by these method range
between 50 to 80 copies / ml .Viral load should be undetectable within 3-6
months of  therapy, failure to do so indicates that the drugs are not effective.
VIRAL CULTURE
This provides the most direct  evidence of HIV infection and it requires
high degree of expertise. Autologous/ Heterologous PBMNC activated  with
mitogens  are co-cultivated with  infectious material for about 28 days .The
presence of virus  is detected by the presence of P24 antigen / RT enzyme in
culture supernatant.
It is rarely used to make diagnosis  and it is mainly  used  for research
purpose.
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SURROGATE MARKERS
1. CD4 / CD8  COUNTS
2. Neopterin
3. Beta 2 microglobulin
4. HIV P24 antigen
CD4 COUNTS
CD4 cells are a type of lymphocyte (white blood cell) which are
important part of the immune system. .Researchers can tell these cells apart by
specific proteins on the cell surface. A T-4 cell is a T-cell with CD4 molecules
on its surface. This type of T-cell is also called “CD4 positive,” or CD4+.
WHY ARE CD4 CELLS IMPORTANT IN HIV?
When HIV infects humans, the cells it infects most often are CD4 cells.
The virus becomes part of the cells, and when they multiply to fight an
infection, they also make more copies of HIV.When someone is infected with
HIV for a long time, the number of CD4 cells they have (their CD4 cell count)
goes down. This is a sign that the immune system is being weakened. The
lower the CD4 cell count, the more likely the person will get sick.
There are millions of different families of CD4 cells. Each family is
designed to fight a specific type of germ. When HIV reduces the number of
CD4 cells, some of these families can be totally wiped out,one can lose the
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ability to fight off the particular germs those families were designed for. If this
happens, they  might develop an opportunistic infection .
DIAGNOSIS OF HIV INFECTION IN THE NEW BORN
Early diagnosis of HIV infection in infants is essential to institute ART
& prophlylactic therapies and at the same time minimize the potential toxicity
of these therapies in exposed uninfected children.
The conventional HIV antibody test cannot be used to make diagnosis
of HIV in the newborn as maternal antibodies are can be detected even in
uninfected newborn for up to a period of 18 months
Test used for  early diagnosis of Congenital HIV infections .
1. Detection of IgA and / IgM anti HIV antibodies
IgA antibodies  appear by 3-4 months of age and IgM by 6 months of
age. IgA after 3 months has a  sensitivity of about 97.6%  and specificity of
about  99.7% .IgM production is erratic and gives false positive results.
However serological markers  in the child are not reliable due to the transient
presence of these markers. Hence virological  test are used for the  diagnosis of
HIV infection in the newborn.
Current practice is to test infants born to HIV infected women at the
ages of
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 48 hours
1 –2 months
3-6 months.
A positive virological at any age suggest the possibility  of HIV
infection and should be confirmed by second test as soon as possible. However
a negative ELISA done between 6 –18 months in the absence of clinical
disease rules out HIV  infection. If only one PCR can be done due to cost
constraints  it is best performed between 3- 6 months of age. Cord blood should
not  be use for HIV testing as there can be contamination.
MANAGEMENT OF HIV INFECTED CHILDREN: (2)
           The advent of many powerful  antiretroviral agents and recognition of
common diseases that attack the children along with powerful monitoring tools,
has helped ensure longevity and improve quality of life in the HIV affected
children. Although the pathogenesis of human immunodeficiency virus (HIV)
infection and the general virologic and immunologic principles underlying the
use of antiretroviral therapy are similar for all HIV-infected persons, there are
unique considerations needed for HIV-infected infants, children, and
adolescents, including a) acquisition of infection through perinatal exposure for
many infected children; b) differences in diagnostic evaluation in perinatal
infection; c) differences in immunologic markers (i.e., CD4+ T cell count) in
young children;(30) d) changes in pharmacokinetic parameters with age caused
by the continuing development and maturation of organ systems involved in
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drug metabolism and clearance; e) differences in the clinical and virologic
manifestations of perinatal HIV infection secondary to the occurrence of
primary infection in growing, immunologically immature persons.
                For making rational decisions in treatment of HIV infected children ,
a proper  knowledge of the antiretroviral agents, their indications, situations in
which they may be changed, other drugs that prevent opportunistic infections
and others for supportive care, is a must. In addition we must have an idea of
how to respond to various clinical scenarios in HIV infected pregnant mothers
in order to prevent HIV in their children as well as about vaccination schedules
in the children.
ANTI RETRO VIRAL THERAPY: (4,9.,10)
Right from 1986 when Zidovudine ushered in the era of antiretroviral
therapy, there has been an explosion in research and introduction of drugs for
the treatment of HIV.
Despite the numerous drugs available the harsh truth is that HIV is not
curable – with any form of therapy. Anti-retro viral therapy only prolongs life.
It may delay the onset of clinical disease and in case the disease is already
symptomatic  reduce the  morbidity.
In resource poor country like ours – India, where cost is the most
important factor limiting therapy, the process of choosing appropriate drug has
been simplified with the introduction of several regimens by the WHO.
30
These regimens were selected on basis of – low toxicity, efficacy and
cost effective.
On behalf of GOI, Union ministry of health and family welfare has
started a programme for providing  ART from 1st of April 2004  free of cost  to
HIV patients. This will concentrate on the following groups of people.
a. Seropositive mothers under PPTCT programme
b. Seropositive children< 15 yrs
c. HIV patients seeking therapy from govt. hospitals
The goals of ART are
1. Reduction of HIV related morbidity
2. Improvement in the quality of life of the child
3. Restoration or preservation of immunological function
4. Maximal durable suppression of viral load.
WHO has also developed guidelines for  the initiation of ART  for the
pediatric population  based on clinical staging and also the virological test
results and CD4 counts or in case this is not available – total lymphocyte count
.  This is due to the fact that infection in the pediatric age group  is complicated
by the passive transfer of viral antigen and antibody from the mothers  serum.
The specific guidelines are in case CD4 count is available,
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a. for children less than 18 months –
Virologically positive – treatment is begun for
1.Stage III disease irrespective of CD4 count
. 2.Stage I and II CD4 count less than 20%
         Virological test not available – mother HIV positive
Stage III disease CD4 count less than 20%
b. for children more than 18 months –
                                  HIV antibody test positive
1. Stage III disease irrespective of CD4 count
2. Stage I and II CD4 count less than 15%
In case if CD4 count is not available, the following criteria is used,
a. For children less than 18 months
Virologically positive – treatment is begun for
1. Stage III disease and AIDS defining illness
2. Stage I and II disease TLC < 2,500
Virological test not available- mother HIV positive
1. Stage III treatment not recommended except AIDS
defining disease
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b. For children greater than 18 months and HIV antibody test
positive
1. Stage III
2. Stage I/II – consider if TLC<1,500.
The various CD4 counts for various age groups for starting therapy:
In less than 12 months CD4 < 20% is equivalent to Absolute CD4 count
< 1000/cu mm.  In the age group 12-18 months CD4 count <20% corresponds
to < 750/cumm.  In the age group 1-5 years CD4< 15% corresponds to <500 /
cumm and in the age group > 6 years <200/cumm.
What to initiate?
Despite the availability of several drugs   in each group of  anti-retro
viral drugs , WHO has  selected 13 drugs for use in  regimens to be used  in
resourse poor countries like  India..
Following are the Drugs approved by WHO for ART,
1. Nucleoside reverse transcriptase inhibitors – zidovudine,
didanosine, stavudine, lamivudine and abacavir.
2. Nucleotide reverse transcriptase inhibitors – tenofovir disoproxil
fumarate.
3. Non-nucleoside reverse transcriptase inhibitors – nevirapine and
efavirenz
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4. Protease inhibitors- saquinavir, ritonavir, indinavir, nelfinavir and
lopinavir/ritonavir.
First line regimen  recommended by WHO  is Stavudine + Lamivudine
+ Nevirapine. Stavudine and lamivudine is available as Fixed Dose
Combination (FDC).
Second line regimen – recommended by WHO is Zidovudine +
Didanosine + nelfinavir.
When to change Anti Retro viral therapy?
Decisions must be based on the following factors:
a) Virologic Considerations
• Less than a minimally acceptable virologic response after eight to
12 weeks of therapy.
• HIV RNA not suppressed to undetectable levels after four to six
months of antiretroviral therapy.
b) Immunologic Considerations
• Change in immunologic classification on the worse side.
• A rapid and substantial decrease in absolute CD4+ T cell count
c) Clinical Considerations
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Progressive neuro-developmental deterioration.
• Growth failure defined as persistent decline in weight-growth
velocity despite adequate nutritional support and without other
explanation.
• Disease progression defined as advancement from one pediatric
clinical category to another
Dosages and Adverse reactions of the more commonly used anti
retroviral agents(5,8)
Dosage Adverse Reactions
Drug Oral dosages only More common Less commonbut important
Zidovudine
(zdv, azt)
Age: 0-90 days: 2
mg/kg/dose 6th hourly
>90 days old:
160mg/m²/dose 8th hourly
Anemia,
Granulocytopenia
Hepatotoxicity
Myopathy
Lamivudine
(3tc)
Age: 0-30
days:2mg/kg/dose 12th
hourly
>30 days old:4mg/kg/dose
12th hourly
Headache,fatigue,
GI intolerance,Rash
Pancreatitis,
Peripheral
Neuropathy
Stavudine
(d4t)
 1 mg/kg/dose 12th hourly GI intolerance
Headache
Peripheral
Neuropathy,
Pancreatitis
Nevirapine
(NVP)
0-8 years:
7 mg/kg/dose
12th hourly
>8 years: 4mg/kg/dose
12th hourly
Rash,Headache
GI intolerance
Hepatotoxicity
PROPHYLAXIS AGAINST OPPORTUNISTIC INFECTIONS:(11,19)
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Pneumocystis carinii(16)
Indication: HIV-infected or HIV-indeterminate, infants aged 1-12 mo;
HIV-infected children aged 1-5 yr with CD4+count <500/µL or CD4+
percentage <15%;
HIV-infected children aged 6-12 yr with CD4+ count <200/µL or
CD4+percentage <15%.
First Choice:Trimethoprim-sulfamethoxazole (TMP-SMZ), 150/750
mg/m²/d in 2 divided doses po t.i.w. on consecutive days
Acceptable alternative dosage schedules:
Single dose po t.i.w. on consecutive days;
2 divided doses po q.d.; 2 divided doses po t.i.w. on alternate days
Mycobacterium tuberculosis (17)
Indication: Mantoux reaction, >5mm or prior positive mantoux result
without treatment; or contact with any case of active tuberculosis regardless of
mantoux result
First Choice: Isoniazid 10-15 mg/kg (max 300 mg) po q.d. x 9 mo or 20-
30 mg/kg (max 900) mg po b.i.w. x9 months .Rifampin, 10-20 mg/kg (max 600
mg) po q.d. x 4-6 mo
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Multidrug-(isoniazid and rifampin) resistant: Choice of drugs requires
consultation with public health authorities and depends on susceptibility of
isolate from source patient
Mycobacterium avium complex
Indication : For children aged >6 yrs, CD4+ count <50/µL;
aged 2-6 yrs CD4+ count <75/µL; aged 1-2 yrs, CD4+ count <500/µL;
aged <1 yr, CD4+ count <750/µL
First Choice: Clarithromycin 7.5 mg/kg (max 500 mg) po b.i.d. , or
azithromycin, 20 mg/kg (max 1,200 mg) po q.w.
Varicella zoster virus :
Indication: Significant exposure to varicella or shingles with no history
of chickenpox or shingles
First Choice: Varicella zoster immune globulin (VZIG), 1 vial (1.25
mL)/10 kg (max 5 vials) im, administered <96 hrs after exposure, ideally
within 48 hrs
Toxoplasma gondii:
Indication: IgG antibody to Toxoplasma and severe immunosuppression
First Choice: TMP-SMZ, 150/750 mg/m2/d in 2 divided doses po q.d.
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Dapsone (children aged >1 mo), 2 mg/kg or 15 mg/m2 (max 25 mg) po
q.d. plus pyrimethamine, 1 mg/kg po q.d. plus leucovorin, 5 mg po every 3
days
Invasive bacterial infections:
Indication:Hypogamma-globulinemia (i.e., IgG <400 mg/dL)
First Choice: IVIG (400 mg/kg every 2-4 wks)
Cryptococcus neoformans:
Indication: Severe immunosuppression
First Choice: Fluconazole, 3-6 mg/kg po q.d.
Alternatives: Itraconazole, 2-5 mg/kg po every 12-24 h
Clearcut guidelines on when to stop these prophylactic
chemotherapeutic agents are yet to emerge.For most diseases, life long therapy
with the above mentioned drugs, is warranted if the drug has to be given for
prevention of recurrence of disease after the first episode.
PRINCIPLES OF IMMUNIZATION  FOR HUMAN
IMMUNODEFICIENCY VIRUS-INFECTED CHILDREN:
General principles of immunization in such children include the
avoidance of Live Viral and Bacterial vaccines in the severely
immunocompromised children.
Other recommendations include:
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Infants born to HBsAg- positive mothers should receive Hep B and 0.5
mL hepatitis B immune globulin (HBIG) within 12 hours of birth at separate
sites. The second dose is recommended at age 1- 2 months and the third dose at
age 6 months. Infants born to mothers whose HBsAg status is unknown should
receive Hep B within 12 hours of birth. Maternal blood should be drawn at
delivery to determine the mother's HBsAg status; if the HBsAg test is positive,
the infant should receive HBIG as soon as possible (no later than age 1 week).
All children and adolescents (through age 18 years) who have not been
immunized against hepatitis B should begin the series during any visit.
All children should receive four doses of IPV at age 2 months, age 4
months, between ages 6 and 18 months, and between ages 4 and 6 years. Oral
poliovirus vaccine should not be administered to HIV infected persons or their
household contacts. However there is some controversy on this issue.
Supportive therapy: Even before the antiretroviral agents were
available,a significant impact on quality of life & survival of HIV infected
children was achieved with intensive supportive therapy. Close attention
should be given to nutritional status which is often delicately balanced and may
require aggressive pre-emptive intervention to achieve adequate caloric and
protein intake . Regular developmental evaluations with necessary physical &
speech therapies  are a must.
Considerations Regarding the Use of Antiretroviral Drugs by HIV-1-
Infected Pregnant Women and Their Infants(6):
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Pregnant women with HIV infection must receive standard clinical,
immunologic, and virologic evaluation. The three-part ZDV chemoprophylaxis
regimen, initiated after the first trimester, should be recommended for all
pregnant women .
HIV-1 infected women receiving antiretroviral therapy in whom
pregnancy is identified after the first trimester should continue therapy. ZDV
should be a component of the antenatal antiretroviral treatment regimen after
the first trimester whenever possible. If therapy is discontinued during the first
trimester, all drugs should be stopped and reintroduced simultaneously to avoid
the development of drug resistance.
In HIV-Infected Women in Labor Who Have Had No Prior Therapy
Several effective regimens are available . These include the following:
1. single dose nevirapine at the onset of labor followed by a single
dose of nevirapine for the newborn at age 48 hours;
2. oral ZDV and 3TC during labor, followed by one week of oral
ZDV/3TC for the newborn;
3. intrapartum intravenous ZDV followed by six weeks of ZDV for
the newborn; and
4. the two-dose nevirapine regimen combined with intrapartum
intravenous ZDV and six week ZDV for the newborn.
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In Infants Born to Mothers Who Have Received No Antiretroviral
Therapy During Pregnancy or Intrapartum, ZDV should be initiated as soon as
possible after delivery--preferably within 6-12 hours of birth. Some clinicians
may choose to use ZDV in combination with other antiretroviral drugs. The
infant should undergo early diagnostic testing so that if HIV-infected, treatment
can be initiated as soon as possible.
Exclusive Breast feeding can be given to these children in the first 4-6
months. Then it must be stopped abruptly when top feeding or weaning foods
are started, as continuation of Breast milk in addition with other feeds results in
higher transmission rates.
Summarizing, a multi disciplinary team approach is desirable for
successful management. Necessary components in this approach  are methods
for monitoring of clinical /nutritional/growth status, appropriate anti-retroviral
regimen, monitoring of therapy, prophylaxis against opportunistic infection,
appropriate immunization, adequate supportive care and counseling as and
when required. Love, affection and optimism from all the caregivers can do
wonders to the mental health of HIV infected child. However, universal HIV
testing with patient notification and reduction of perinatal transmission holds
the key to phenomenal success in the management of HIV infected children.
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REVIEW OF LITERATURE
Costella et al (46) compared the total lymphocyte count to CD4
lymphocyte cells count in 839 adult patients with HIV in Thailand. Their study
found out a correlation of 0.67 between both these factors. It also showed a
higher correlation (0.72) for the female sex than in males (0.68) .Subset
analysis by WHO clinical stages revealed a higher correlation (0.73) in the
more  severe disease groups ( II & III) than in Group I. Their study was one of
the few studies that combined correlation coefficients for hemoglobin as well
as total lymphocyte counts and compare to them to CD4 + T lymphocyte cell
count. It showed that such an approach was more accurate in predicting CD4 +
T lymphocyte cells.
Mahajan et al(45), from Los Angles conducted a study that compared
total lymphocyte count with CD4 + T lymphocyte cell count following the
initiation of HAART. Their study showed that decrease in the CD4 + T
lymphocyte cell counts following HAART was closely paralleled by a
corresponding and highly correlative decrease in total lymphocyte count also.
This change however continued only upto two years of HAART therapy.
Though this was one of the few studies that tried to analyse the correlation
following HAART. This study was also hampered by the small sample size
(126 patients).
Elna Van der ryst et al and Marinde et al (28) measured CD4 counts and
total lymphocyte counts of 2777 HIV seropositive patient visiting the
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immunology clinic at pelonomi hospital in South Africa between 1991 –1997,
which accounted for 3237 observations of CD4 counts, CD4%, Total
lymphocyte counts and CD8 T cells.   Spearman rank correlation was
calculated between total lymphocyte counts and CD4 counts. There was a high
degree of correlation ( R=0.7060) between CD4 counts  and total lymphocyte
counts.
Kumarasamy et al and Mahajan(34) et al assessed the correlation between
CD4 counts and total lymphocyte counts in HIV seropositve patients attending
an HIV / AIDS clinic at Chennai. Positive predictive value negative predictive
value, and sensitivity and specificity of various total lymphocyte cut off were
computed for CD4 counts < 200 cells /mm3 and < 350 cells / mm3. High
degree of correlation (0.744) was noted between 650 paired CD4 and total
lymphocyte counts. Total lymphocyte counts < 1400 cells had 76% positive
predictive value and 86% negative predictive value and was 73% sensitive and
88% specific for CD4 counts <200 cells /mm3. Total lymphocyte count <1700
cells /mm3 had 86% PPV, 69% NPV and was 70% sensitive 86% specific for
CD4 counts <350 cells /mm3. This is one of the very few studies done in
Indian Population. They concluded that total lymphocyte could serve as low
cost tool for determining both the patient risk of opportunistic infection and
when to initiate prophylaxis in resource constrained settings.
E.J. Beck et al, and Kupek et al(38)assessed the correlation between total
lymphocyte count, an absolute CD4 counts in HIV seropositive patient
managed  at St.Marys Hospital , London. Spearman partial rank correlation
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was calculated between total lymphocyte count and absolute CD4 counts,
CD4% stratified by stage of HIV infection. There was a high degree of
correlation between 1534, paired absolute lymphocyte counts and CD4
lymphocyte counts. When analyzed by stage of HIV infection the correlation
increased from  (R=0.64)  for asymptomatic patients to( R= 0.72) for patients
with symptomatic non AIDS HIV and to (R=0.73) for AIDS patients. The high
degree of correlation between total lymphocyte count and CD4 lymphocyte
counts especially for symptomatic AIDS patients demonstrates the suitability
of total lymphocyte counts  as a marker of immune status especially where
CD4 counts are not available.
Post et al(39) compared total lymphocyte counts and CD4 lymphocyte
counts of 831 HIV / AIDS patients from Cape Town, South Africa as
predictors of developing AIDS /death. They concluded that a total lymphocyte
count < 1200/mm3 and a CD4 count <200 cells /mm3 were equal predictive of
disease progression and that a total lymphocyte count of 1200/mm3 could be
used as cutoff for initiating cotrimoxazole  prophylaxis.
Stebbing et al and Sawleshwarhar et al studied the utility of total
lymphocyte count in place of CD4 count to predict the development of AIDS
defining opportunistic infection.
CD4 lymphocyte count and total lymphocyte count were recorded in
those people who had a first episode of an AIDS defining  opportunistic
infection   . Pearson correlation coefficient was 0.70 between these variables
with a   P value of less than 0.001 which was stastically significant. Patients
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with total lymphocyte counts of 1000 –1500 cells/mm3 were estimated to be  at
40% increased risk of developing AIDS defining opportunistic infection ,
whereas patient with CD4 count of 150-200 cells /mm3 were at 34% increased
risk of developing an AIDS  defining  opportunistic infection. They concluded
that total lymphocyte count can be used as reliable predictors of AIDS defining
opportunistic infection in HIV infected people and as such total lymphocyte
count can also be used to facilitate decision about timing of HAART and.
AIDS  defining  opportunistic infection prophylaxis.
Motasim Badri et al and Robinwood et al(40)   assessed the usefulness of
total lymphocyte count in monitoring highly active anti retroviral  therapy  in
266 patients attending HIV  clinic / research unit at somerset hospital
capetown.CD4 count and total lymphocyte counts were measured from
baseline  at  4,8,12,48 weeks after initiation of highly active antiretroviral
therapy. The median increase in total lymphocyte counts was 30, 52,139 and
219 cells X 106 / l, median increase in CD4 count was 8,48,88 and 145 cells X
106 /l.
There was a high degree of correlation ( R=0.611) between  all pairs of
CD4 count and total lymphocyte counts. Total lymphocyte count correlated
well with changes in CD4 cell count. They concluded total lymphocyte may
have a role in inexpensive monitoring of immunological response to HAART
resource constrained settings.
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STUDY JUSTIFICATION
More than 90% of HIV infected individuals reside in resource-
constrained countries[1]. In resource-rich settings, CD4 cell count and HIV-1
RNA concentration are measured regularly in HIV-infected individuals to
guide decisions about opportunistic infection prophylaxis ,antiretroviral
therapy initiation and maintenance. In some settings, the cost of monitoring
HIV-1 treatment now exceeds the cost of antiretroviral drugs[33]. As initiatives
to provide antiretroviral therapy in resource-poor settings are being undertaken,
it is important to evaluate alternative assays that could guide treatment
decisions. Current guidelines recommend that decisions involved in initiating
and changing antiretroviral therapy be guided by the immune category of
children, based on their CD4 cell counts. Where CD4 count testing is not
available or too expensive for routine use, the WHO recommends the use of
total lymphocyte count (TLC) to monitor the immune response to HAART.
TLC is an inexpensive and widely available laboratory parameter.  TLC is
easily obtained from the routine complete blood count (CBC) with differential
by multiplying percentage lymphocytes by white blood cell count.  In southern
India for example, the cost of a single TLC from a CBC is less than 100 rupees
while a single CD4 count by flow cytometry is approximately 1500 rupees.
There are no of studies examining the correlation between total lymphocyte
counts and CD4  counts in HIV +ve adult patients.There is no published data
examining the correlation  between  total lymphocyte counts and CD4  counts
in HIV seropositive  pediatric patients. In  our study we have examined the
correlation between  total lymphocyte counts and CD4  counts in HIV infected
children between 2 to  12 years of age.
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AIM OF THE STUDY
PRIMARY OBJECTIVE
To study the correlation between total lymphocyte counts and CD4
lymphocyte counts of children belonging to stages I , II and III of WHO
staging for AIDS.
SECONDARY OBJECTIVE
To establish arbitrary cut off values of total lymphocyte counts that
correspond to CD4 counts less than 500/mm3 in the age group 2 – 5 years and
less than 200/ mm3 in 6 – 12 years age group.
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MATERIALS AND METHODS
Study Design :
Descriptive study
Study period :
07/07/2004 to 15/08/2005
Study place :
Institute of Child Health &Hospital for Children ,Chennai
Study population :
All children between 2 and 12 years diagnosed as having HIV positivity,
by means of  repeatedly positive ELISA, who were admitted in, or referred to,
our Institute.
SAMPLE SIZE
With a α - error of 0.05 and a power of the study corresponding to 80%
and with previous study of Kumarasamy et al., based on adults showing a
correlation of 0.744 and with an expected correction 0.70, sample size
calculated statistically for this study to show meaningful results was 150.
MANEUVER
A thorough history and clinical examination was performed in all these
children, the details of which were noted in a predesigned  proforma. These
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included age, sex, risk factors for HIV infection, time of onset of symptoms,
duration of symptoms, examination findings with special reference to growth
failure, fever, hepato-megaly, splenomegaly, lymphadenopathy, parotitis,
diarrhea, secondary infectious diseases and other associated diseases. . Routine
laboratory investigations including a complete blood count, X-ray chest,
Mantoux test and urine and stool examination was done in all children. Specific
investigations which included cerebrospinal fluid (CSF) examination, gastric
lavage for acid fast bacilli (AFB), fine needle aspiration cytology (FNAC),
blood culture, relevant imaging studies were done when indicated.Their parents
were screened for HIV positivity by means of ELISA. Siblings were also
screened for HIV positivity.
CD4 counts and Total Lymphocyte Counts were measured on the same
blood sample taken in EDTA coated tubes. The total and differential cell
counts were determined using an automated hematology analyzer (Abx,
France) and TLC was derived from the CBC by multiplying lymphocyte
percentage by the white blood cell count. CD4%, was measured in whole blood
using a 3 colour panel purchased from Beckman coulter,USA, using a standard
protocol.The monoclonal anti CD4 antibody was directly conjugated with RD1
(phycoerythrin), anti CD8 with fluorescin isothiocyanate and anti CD3 with
PC5. The cells were analysed on a Beckman coulter Epics Altra flowcytometer
cum sorter using EXPO32 multiCOMP software. Data was collected for 10,000
cells for each tube and displayed as dot plots. Dual positive CD3+ CD4+ and
CD3+ Cd8+ cell % were measured and the absolute CD4 count was derived by
multiplying CD4% and TLC. They were given supportive treatment mainly
49
consisting of PCP prophylaxis, nutritional support, control of other infections,
anti-tuberculous therapy wherever applicable.The option of Anti Retro-Viral
therapy was discussed with the caregivers. .
STATISTICAL ANALYSIS
Correlation between CD4 count and total lymphocyte count was
assessed by computation of spearman rank order correlation for all paired count
Sensitivity, specifity, positive predictive value and negative predictive
value of various total lymphocyte counts ranges were calculated for CD4 count
< 200 cell/mm3 in the age group 6-12 and CD4 count < 500 cells /mm3 in the
age group 2- 6 years.
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RESULTS
150 patients were included in the original study group based on the
statistically derived sample size. Since 2 of these patients had significantly
elevated TLC and CD4 cell counts that skewed the ananlysis of data for
correlation, these two samples were excluded from the study. The remaining
148 pairs of values were taken into consideration for the calculation of
spearman rank correlation coefficients between TLC and CD4 cell counts.
Table:1
Demographic Details of the Study Population
Demographic data
No. of
children n
No.of
children in %
2-5 91 61.5Age group
(years) 6-12 57 38.5
M 99 66.9Sex distribution
F 49 33.1
Mother + 122 81.3
Mother - 4 2.1
Mother status
NK
25 16.5
Father + 94 62.5
Father - 16 10.4
Parental
HIV status
Father status
NK
41 27.1
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Table : 2
Mode of Transmission of HIV in Study Population
Mode of transmission No. of children( n) No . of children in %
MTCT 131 87.3
Blood 1 .0066
Not known 18 12
87.3% of HIV infected children were infected  by vertical transmission ,
only 1 case of  confirmed HIV was discovered to have been  transmitted by
blood transfusion . In 12% of the children mode of transmission could not   be
found because parents could not be screened and some of these children were
from orphanages
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Table - 3
Clinical categorization of Study Population according
to WHO STAGING
WHO staging Frequency Percent
I 15 10.1
II 92 62.2
III 41 27.7
The study population was categorized in to  groups according WHO
clinical staging. Majority of these children belonged to stage II  (62%) and
27% of the children belonged to stage III.
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Table - 4
Immune categorization of Study Population
Immune category
No. of
children by
CD4+ T cell
count
% of
children by
CD4+ T cell
count
No. of
children by
CD4+ T cell
%
% of
children by
CD4+ T cell
%
No evidence of
immunosuppresion
21 14.2 1 .7
Evidence of moderate
immunosuppresion
96 64.9 82 55.4
Evidence of severe
immunosuppresion
31 20.9 65 43.9
Immune categorization was done on these children based on CD4
lymphocyte count and CD4 lymphocyte percentages. 64% of the children and
55% of the children were moderately immune suppressed  based on their  CD4
counts and CD4 percentages respectively.
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Table - 5
Spearman rank correlation coefficient between total lymphocyte count
and CD4 count in the entire study population
Total lymphocyte count CD4 count
Total lymphocyte count 1.000 .797
CD4 count .797 1.000
The spearman correlation coefficient for CD4 to total lymphocyte  was
0.797  in the study population
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Table - 6
Spearman rank correlation coefficient between total lymphocyte count
and CD4 count in groups stratified based on who clinical stagings
WHO
Staging CD4 count
Total lymphocyte
count
CD4 count 1.000 .887
I
Total lymphocyte count .887 1.000
CD4 count 1.000 .843
II
Total lymphocyte count .843 1.000
CD4 count 1.000 .712
III
Total lymphocyte count .712 1.000
Spearman rank correlation was analyzed in children belonging to
different stages of WHO staging of AIDS. The correlation coefficient was
0.887 in WHO stage I and 0.712 in WHO stage III.
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Table - 7
Spearman rank correlation coefficient between total lymphocyte
count and CD4 count in groups stratified according to age
Age Group CD4Count
Total
Lymphocyte
Counts
CD4 Count 1.000 .791
2-5 years
Total Lymphocyte counts .791 1.000
CD4 Count 1.000 .823
6-12 years
Total Lymphocyte counts .823 1.000
The correlation coefficient was 0.791 in the age group 2-5 years, 0.823
in the age group 6-12 years.
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Table - 8
Positive predictive value (PPV), negative predictive value (NPV),
and sensitivity and specificity of various TLC cutoffs for CD4
counts <500cell /mm3   in children between 2-5 years
TLC cutoff Sensitivity Specificity PPV NPV
<2000 35 100 100 87
<2500 47 100 100 89
<3000 65 100 100 93
<3500 82 78 48 95
<4000 82 75 38 96
<4500 94 69 36 98
<5000 94 53 27 98
<5500 100 37 23 100
A total lymphocyte count value of < 3500 cells/ mm3 had a sensitivity of
82% and a specificity of 78% for a correlation with a CD4 lymphocyte  count
of < 500 cells/mm3.
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Table - 9
Positive predictive value (PPV), negative predictive value (NPV),
and sensitivity and specificity of various TLC cutoffs for CD4
counts <200cell /mm3   in children between 6-12 years
TLC cutoff Sensitivity Specificity PPV NPV
<1000 36 98 83 82
<1500 86 86 67 95
<2000 86 55 44 90
<2500 93 54 39 96
<3000 93 35 32 94
<3500 100 14 27 100
A total lymphocyte count value of < 1500 cells/ mm3 had a sensitivity
and  specificity of 86% for a correlation with a CD4 count of < 200 cells/ mm3
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DISCUSSION
CD4 lymphocyte are the principal targets of HIV and progressive
decline of these cells over time takes  place in HIV infection. CD4 T
lymphocyte count is  a  useful  indicator of disease progression and is widely
used to determine points at which prophylaxis  against opportunistic infections
should be instituted  and also for monitoring response to HAART. However
owing to the high cost and need for specialized equipment and wide spread and
routine use of CD4 count in the management of HIV infection has not been
possible.  There is a need for simpler ,cheaper surrogate markers to monitor
HIV disease  progression especially in resource limited settings such as ours.
WHO guidelines now recommends that immune categorization and initiation of
HARRT be based on clinical indicators in association with basic laboratory
tests like total lymphocyte counts and hemoglobin. Though reports suggesting
that total lymphocyte counts is a reliable surrogate marker of immune status in
adults  no such study is available where children with HIV are concerned.
This study aimed at finding out any correlation that exists  between total
lymphocyte counts and CD4 T cell counts if any and also strength  of any such
correlation.
Previous studies have also attempted a similar correlation between total
lymphocyte counts and CD4 lymphocyte counts  in adults.
The correlation obtained between TLC and CD4  counts in the studies
as follows.
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Beck et al(38) from Newcastle general hospital in London found an
correlation of 0.76 between CD4 and total lymphocyte counts in the whole
group of patients.
Rysst et al(42) from Bloem fontein in South Africa  observed  a
correlation of 0.704 between total lymphocyte counts and CD4 counts.
Kumaraswamy et al(34) discovered a correlation of 0.744 in 650
samples.This was an Indian study in adults.
Motasim Badri et al (40)in his study  of 26 patients in  somerset  should a
correlation of 0.61.
Speech et al in a large study involving  1451 patients between  the ages
24-62 years  found  a correlation  of 0.72.
All the above studies have been conducted in adults. The situation in
children regarding such a correlation in more complex and there have been
very few studies conducted in children in this aspect.
Unpublished data received by personnel communication from
Dr.Sowmya Swaminathan in Chennai should a correlation of 0.71%. This has
been the only pediatric study that has been Conducted so  far in India.
In our study the correlation obtained was 0.797. This has been the
highest correlation obtained so far in a study in children conducted in India.
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The correlation coefficient is comparable with those of various adult
studies indicating that that total lymphocyte counts can be used a surrogate
marker of immune status of HIV affected children. Strength of correlation is
sufficient to allow a wide confidence interval when predicting CD4
lymphocyte counts based on total lymphocyte counts.
We also calculated the correlation coefficient for different age groups
since there is a variability in the total lymphocyte counts and CD4 counts
especially in younger age groups .Composition of the various lymphocyte
subgroup undergoes significant changes as  age advances.
A previous study should be correlation coefficient of 0.67 in 1-5 years
ages and 0.74 in 6-12 years.  In our study we obtained a correlation coefficient
of 0.791 in the age 2-5 years age group and 0.823  in the 6-12 years age group.
The value was similar to that obtained in the total group of patients indicating
that even in the younger age group total lymphocyte counts can be used as
surrogate markers. Correlation coefficient were also obtained in the various
subgroups of patients based on WHO staging .Though previous studies in
adults showed that the degree of correlation measured increased as the severity
of disease progressed (Beck et al(38), Rysst et al(42)). Our study showed that the
degree of correlation weakened as severity of disease progressed but not to a
very significant extent (stage I-R =0.887 ;  Stage II  R=0.843 Stage III
R=0.712).
Though we had a smaller sample size since this was one of the few
studies done in children  regarding  this aspect, we also tried to establish
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various cutoff values of total lymphocyte counts for severe stages of
immunosuppression in the age group of 2-5 years and 6-12 ages. These cutoff
value of total lymphocyte count correspond to CD4 counts of  200/mm3 and
500/mm3. It is these values of CD4  count which are considered for initiation of
HAART and well as prophylaxis for various Oppurtunistic Infection. A cut off
value total lymphocyte count that corresponds closely with these value of CD4
count would help immensely in practical  management of HIV infected
children . Similar cutoff values were established in previous adult studies. One
of these studies done by Kumarasamy et al(34)  suggested that  total lymphocyte
count of less than 1400 /mm3 corresponds to a CD4 lymphocyte count of less
than 200/ mm3 and a total lymphocyte count less than 1700/ mm3 correspond to
CD4 count less than 350/ mm3This study also suggested that selection  of
appropriate total lymphocyte  cutoff  should be made only on a regional basis
taking in to consideration such as incidence of OI ,local antimicrobial
resistance pattern and available of antimicrobials .we derived a total
lymphocyte count cutoff for 1- 5 years and 6-12 years respectively .
A total lymphocyte  of  <3500/ mm3 correlated with CD4 count < 500/
mm3in the 2-5 years age group and this value had an  sensitivity of 82% and
specificity of 78%. Though lower values such  as total lymphocyte  count
<2500/mm3 had a specificity of 100% they were highly insensitive with
sensitivities ranging to  from 35- 47%  where as with higher values such as
<4000 /mm3 the specificity dropped drastically ,the sensitivity reached 100%
.Similarly we obtained a value of total lymphocyte count<1500 as being 86%
sensitive as well as specific  for CD4 <200 / mm3 in children between 6-12
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years. These values are arbitrary cutoff values that have been derived based on
the WHO definition of severe immunsuppresion in children and as stated by
the previous studies these value also need modification based on locoregional
sensitivity pattern of micro organism and existing level of OI.
Our study has some limitation as we included data from all available
children regardless of there clinical status, presence of tuberculosis and other
opportunistic infections. Most of these children were malnourished and were
on therapy for other infections.  However none were receiving antiretroviral
therapy. Our aim was to be as inclusive as possible in order to get such a result
that would be applicable in a real world clinical setting such as ours, where
HAART and other aggressive modes of therapy are not yet freely available due
to economic and social constraints.
It would be ideal to study a large number of patients using these data
available now as a pilot study. This can be of great use in the resource limited
settings like ours from therapeutic point of view.
Other surrogate to marker for which evaluation is ongoing in various
trails includes hemoglobin. Combined correlation using both total lymphocyte
count and hemoglobin can increase the predictive value of estimating CD4
count based on these surrogate markers.
CONCLUSION
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Correlation coefficient obtained for the whole group of patients between
total lymphocyte count and CD4 count was 0.812.
Correlation was strong in all age groups but strongest in the in the 6-12
years age group. Strength of correlation is comparable with that obtained in
previous adult studies.
Correlation coefficient was also strong in the various subgroups of
patients based on WHO staging (stage I-R =0.887 ;  Stage II  R=0.843; Stage
III R=0.712).
We have shown that a TLC of 3500 cells / mm3 in children, 1-5 years of
age and 1500 cells / mm3   in those aged 6 - 12 years  correlates with a CD4
count of  <500 cells / mm3 and 200 cells / mm3 respectively, with a sensitivity
and specificity between  78 - 86%.
TLC can be used as a surrogate marker of immune status in resource
poor settings such as ours instead of CD4 lymphocyte counts.
Surrogate markers such as hemoglobin which is another easily available
investigation, in most health care centre, even in resource restricted settings,
need to be evaluated further.
A correlation coefficient combining the total lymphocyte count and
hemoglobin can be more useful than either of the two, both for predicting CD4
lymphocyte count and also the cut off values for initiating HAART.
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ANNEXURE - I
PROFORMA
Name :
Age :
Sex :
Mode of Delivery
& Perinatal Details :
Parental HIV Status :
Age of Presentation :
Clinical Features : Duration of Symptoms
Failure to Thrive
Recurrent Diarrhea
Prolonged Fever
Recurrent respiratory tract infections.
General Examination :
Systemic Examination
CVS :
RS :
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ABDOMEN :
CENTRAL NERVOUS SYSTEM
LABORATARY INVESTIGATIONS :
COMPLETE BLOOD COUNT &
PERIPHERAL SMEAR :
URINE ROUTINE EXAMINATION :
CHEST X-RAY :
MANTOUX :
SPUTUM FOR AFB :
CD4 COUNTS :
CD4 PERCENTAGE :
TOTAL LYMPHOCYTE COUNTS :
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ANNEXURE - II
GRAPH SHOWING CORRELATION BETWEEN CD4 LYMPHOCYTE
COUNTS AND TOTAL LYMPHOCYTE COUNTS IN STAGES I, II, III OF
WHO STAGING FOR AIDS
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ANNEXURE - III
GRAPH SHOWING CORRELATION BETWEEN CD4
LYMPHOCYTE COUNTS AND TOTAL LYMPHOCYTE COUNTS
N AGE GROUP 2 TO 6 AND 6 TO 12 YEARS
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